LOVFF (Cannara Biotech) Marketable Securities: $0.00 Mil (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LOVFF Cannara Biotech Inc LOVFF
84 GF Score
Price $1.38
GF Value $1.21
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cannara Biotech Marketable Securities?

Cannara Biotech LOVFF 84 Marketable Securities is $0.00 Mil as of May. 2026. GuruFocus rates LOVFF with a GF Score™ of 84/100 and a GF Value™ of $1.21 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cannara Biotech's Marketable Securities for the quarter that ended in May. 2026 was $0.00 Mil.

Cannara Biotech  (OTCPK:LOVFF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cannara Biotech Marketable Securities Related Terms

Cannara Biotech Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cannara Biotech's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannara Biotech Marketable Securities Chart

Cannara Biotech Annual Data
Trend Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Cannara Biotech Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LOVFF
84GF Score
Cannara Biotech Inc LOVFF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cannara Biotech Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Cannara Biotech (LOVFF) has a Marketable Securities of $0.00 Mil as of May. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cannara Biotech and its competitors.
Is Cannara Biotech's Marketable Securities too high?
Cannara Biotech's current Marketable Securities is $0.00 Mil. Overall, Cannara Biotech has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's Marketable Securities compare to ZTS and UTHR?
Cannara Biotech's Marketable Securities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cannara Biotech and its competitors. Cannara Biotech's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.21, compared to a current price of $1.38 — trading 13.9% above its estimated fair value. The current Marketable Securities is $0.00 Mil. Cannara Biotech's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current Marketable Securities is $0.00 Mil as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cannara Biotech (LOVFF) Overvalued in 2026?

Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued. The current stock price of $1.38 is trading 13.9% above its estimated GF Value™ of $1.21. GuruFocus considers Cannara Biotech to be Modestly Overvalued.

Key valuation signals for LOVFF:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $1.21 vs. price of $1.38 (13.9% above fair value)
  • GF Score™: 84/100 with 6 warning signs

No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cannara Biotech Business Description

Other Exchanges 8CB0:GermanyLOVE:Canada
Address 1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
84GF Score

Get the complete analysis for LOVFF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.38
Price
$1.21
GF Value